Opus Genetics (IRD) Projected to Post Quarterly Earnings on Friday

Opus Genetics (NASDAQ:IRD) is projected to announce its earnings results before the market opens on Friday, March 14th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter.

Opus Genetics Stock Performance

Shares of NASDAQ:IRD opened at $1.00 on Friday. The stock’s 50 day simple moving average is $1.16. Opus Genetics has a 12-month low of $0.81 and a 12-month high of $1.56. The firm has a market cap of $31.57 million, a price-to-earnings ratio of -0.92 and a beta of 0.16.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Opus Genetics in a report on Wednesday, February 19th.

Insider Transactions at Opus Genetics

In other Opus Genetics news, CEO George Magrath purchased 100,000 shares of the company’s stock in a transaction dated Thursday, December 26th. The stock was purchased at an average price of $0.98 per share, with a total value of $98,000.00. Following the completion of the purchase, the chief executive officer now owns 599,150 shares of the company’s stock, valued at approximately $587,167. The trade was a 20.03 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 6.60% of the stock is currently owned by insiders.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.